Vanguard International High Dividend Yield ETF vs Zoetis Inc — how do they compare? Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard International High Dividend Yield ETF for 50 Days and Zoetis Inc for 70 Days on average.
| VYMI | ZTS | |
|---|---|---|
Market Cap | $22.80B | $30.20B |
Volume | 748,441 | 6,175,327 |
Sector | Broad Market / Factor | Health |
52-Week High | $107.13 | $147.53 |
52-Week Low | $82.92 | $69.09 |
Typical Hold Time | 50 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
VYMI trades at $100.53 with a slight 0.3% daily gain, though technical indicators signal bearish momentum with moving averages showing 11 sell signals versus 2 buy signals. The ETF's recent performance includes a 29% one-year return and 14.13% five-year average annual return, with strong institutional interest as firms like Envestnet increased holdings by 22% in Q2 2026. A dividend of $0.82 is scheduled for payment on September 22, 2026.
The outlook for VYMI is mixed; bullish sentiment from Seeking Alpha highlights sector catalysts in financials, energy, and healthcare supporting dividend growth, while technical bearishness and Fed rate hike impacts pose risks. Investors may find value in its 3.61% dividend yield and global diversification, but should monitor financials exposure (43.6% of holdings) amid rising rates.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →